- Home
- CPRI vs NKTR Comparison
CPRI vs NKTR Comparison
Compare CPRI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRI | NKTR |
|---|---|---|
| Founded | 1981 | 1990 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2011 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CPRI | NKTR |
|---|---|---|
| Price | $14.58 | $46.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $22.22 | ★ $141.40 |
| AVG Volume (30 Days) | ★ 4.3M | 986.3K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.40 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $3,474,000,000.00 | $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.79 | $36.10 |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $12.40 | $33.40 |
| 52 Week High | $28.27 | $109.00 |
Technical Indicators
Market Signals| Indicator | CPRI | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 31.27 |
| Support Level | $12.40 | $54.13 |
| Resistance Level | $16.05 | $76.63 |
| Average True Range (ATR) | 0.68 | 3.61 |
| MACD | 0.03 | -0.92 |
| Stochastic Oscillator | 18.43 | 7.64 |
Price Performance
Historical ComparisonAbout CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.